Cart
sales@molnova.com
SM 16
CAS No. 614749-78-9
SM 16( —— )
Catalog No. M19909 CAS No. 614749-78-9
SM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 80 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 405 | In Stock |
|
| 100MG | 597 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSM 16
-
NoteResearch use only, not for human use.
-
Brief DescriptionSM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
-
DescriptionSM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK4| ALK5
-
Research AreaCancer
-
IndicationCancer
Chemical Information
-
CAS Number614749-78-9
-
Formula Weight430.5
-
Molecular FormulaC25H26N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 60 mg/mL
-
SMILESCc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C12CCC(CC1)(CC2)C(N)=O
-
Chemical Name4-[4-(13-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Suzuki E et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9.
molnova catalog
related products
-
CEP-28122
A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.
-
8-Bromo-cAMP(sodium ...
8-Bromo-cAMP is a long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.
-
ALK-IN-26
ALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.
